Aerpio Pharmaceuticals, Inc. announced that Stephen Hoffman has been appointed Chief Executive Officer, effective as of December 1, 2017, and is expected to be appointed to its board of directors as a Class I director in connection with the commencement of his employment with the company. Dr. Hoffman succeeds Dr. Joseph H. Gardner, who will continue to serve as President and Founder of Aerpio. Hoffman joins the company from PDL BioPharma where he served as Senior Advisor since February 2014.

Prior to that he served as Managing Director at Skyline Ventures from 2007 to 2014 and was general partner at TVM Capital from 2003 to 2007. Prior to TVM, he served as President, Chief Executive Officer and a Director of Allos Therapeutics from 1994 to 2002, where he remained as Chairman until its acquisition by Spectrum Pharmaceuticals, Inc. in 2012. Dr. Hoffman currently serves on the board of directors of Dicerna Pharmaceuticals, Inc. and AcelRx Pharmaceuticals, Inc., Bicycle Therapeutics Ltd., and Palleon Pharmaceuticals, Inc.